Epicutaneous 1-Chloro-2, 4-Dinitrobenzene (DNCB) Patch in HIV Infection.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
To evaluate the efficacy of dinitrochlorobenzene (DNCB) in patients with early HIV infection by monitoring immunologic parameters and serum HIV RNA. To facilitate the understanding of possible alterations in the immunological status of the HIV+ patient cohort.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 55 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patients must have:
EITHER HIV negative or documented HIV+ by both the ELISA and Western blot tests.
For HIV+ patients:
Patients must fail to meet the AIDS-defining criteria.
CD4 lymphocyte count between 200 - 500 cells/mm3.
Patients with obvious ultra violet(UV)-irradiated skin damage in the treatment sites.
Patients who are likely to commence antiretrovirals within the 6-month study period.
Patients using other immunomodulator therapies or other alternative therapies.
Patients likely to require chemotherapy during the course of the study.
Patients who are likely to require significant UV light exposure during the study period.
Patients who are likely to require radiation therapy during the course of the study.
Prior exposure to DNCB.
Patients who have used antiretroviral medications within the previous 3 months.